142 related articles for article (PubMed ID: 19522046)
1. Anti-interleukin-5 therapy and severe asthma.
Szczeklik A
N Engl J Med; 2009 Jun; 360(24):2576-7; author reply 2577. PubMed ID: 19522046
[No Abstract] [Full Text] [Related]
2. Anti-interleukin-5 therapy and severe asthma.
Zarogiannis S; Gourgoulianis KI; Kostikas K
N Engl J Med; 2009 Jun; 360(24):2576; author reply 2577. PubMed ID: 19516040
[No Abstract] [Full Text] [Related]
3. Anti-interleukin-5 therapy and severe asthma.
Gleich GJ
N Engl J Med; 2009 Jun; 360(24):2577; author reply 2578. PubMed ID: 19522047
[No Abstract] [Full Text] [Related]
4. Eosinophils in asthma--closing the loop or opening the door?
Wenzel SE
N Engl J Med; 2009 Mar; 360(10):1026-8. PubMed ID: 19264692
[No Abstract] [Full Text] [Related]
5. [Severe refractory eosinophilic asthma].
Jäger-Becker D
MMW Fortschr Med; 2016 Feb; 158(3):67. PubMed ID: 27119709
[No Abstract] [Full Text] [Related]
6. Novel Interleukin-5 Targeted Treatment Options for Severe Eosinophilic Asthma.
Berendse J; Craig B; Gullickson E
S D Med; 2018 Jun; 71(6):274-276. PubMed ID: 30005153
[No Abstract] [Full Text] [Related]
7. Reslizumab (Cinqair) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
[No Abstract] [Full Text] [Related]
8. [CME: Mepolizumab, an Additional Therapeutic Agent for Severe Asthma].
Platzer S; Fehr T; Latshang T
Praxis (Bern 1994); 2018; 107(21):1129-1135. PubMed ID: 30326819
[TBL] [Abstract][Full Text] [Related]
9. Eosinophils and interleukin-5: the debate continues.
Kay AB; Menzies-Gow A
Am J Respir Crit Care Med; 2003 Jun; 167(12):1586-7. PubMed ID: 12796050
[No Abstract] [Full Text] [Related]
10. The role of interleukin 5 in asthma.
Varricchi G; Canonica GW
Expert Rev Clin Immunol; 2016 Sep; 12(9):903-5. PubMed ID: 27450970
[No Abstract] [Full Text] [Related]
11. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
12. Deal watch: Anti-IL-5 antibody attracts Cephalon to agree option for Ception acquisition.
Nat Rev Drug Discov; 2009 Mar; 8(3):185. PubMed ID: 19247299
[No Abstract] [Full Text] [Related]
13. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
14. Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?
Castro M; Bacharier LB
Lancet; 2016 Oct; 388(10056):2059-2060. PubMed ID: 27609409
[No Abstract] [Full Text] [Related]
15. Reassessing the Th2 cytokine basis of asthma.
O'Byrne PM; Inman MD; Adelroth E
Trends Pharmacol Sci; 2004 May; 25(5):244-8. PubMed ID: 15120489
[TBL] [Abstract][Full Text] [Related]
16. [PERSONALIZED TREATMENT OF ASTHMA: THE ISSUE OF ANTI-INTERLEUKIN-5 ANTIBODIES].
Louis R; Demarche S; Van Hees T; Schleich F
Rev Med Liege; 2015; 70(5-6):306-9. PubMed ID: 26285457
[TBL] [Abstract][Full Text] [Related]
17. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
18. Reslizumab and eosinophilic asthma: one step closer to phenotype-directed therapy?
McCallister JW
Am J Respir Crit Care Med; 2011 Nov; 184(10):1096-7. PubMed ID: 22086982
[No Abstract] [Full Text] [Related]
19. New aspects in the treatment of asthma: targeted therapy.
Wang ZL
Chin Med J (Engl); 2008 Apr; 121(7):640-8. PubMed ID: 18466686
[No Abstract] [Full Text] [Related]
20. Asthma Yardstick Update: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma.
Oppenheimer JJ; Borish L
Ann Allergy Asthma Immunol; 2018 Dec; 121(6):660-661. PubMed ID: 30172715
[No Abstract] [Full Text] [Related]
[Next] [New Search]
